Clinical Study
Covered Metal Stenting for Malignant Lower Biliary Stricture with Pancreatic Duct Obstruction: Is Endoscopic Sphincterotomy Needed?
Table 4
Risk factors for overall complications after CSEMS deployment (univariate analysis).
| | | Complication (+)
() | Complication (−)
() | P value | OR (95% CI) |
| | Female gender | 7 | 32 | 0.770 | 1.2 (0.38–4.1) | | Age (<60 years) | 4 | 4 | 0.022 | 6.9 (1.5–33) | | Nonpancreatic cancer | 4 | 2 | 0.006 | 14 (2.3–89) | | Periampullary diverticulum | 3 | 8 | 0.377 | 2.2 (0.49–9.6) | | Non-EST | 6 | 35 | 0.765 | 0.76 (0.23–2.5) | | Fully covered type stent | 5 | 17 | 0.499 | 1.8 (0.52–6.3) | | Pancreatic duct injection | 3 | 17 | 1.000 | 0.87 (0.21–3.5) | | Biopsy of the bile duct | 0 | 4 | 1.000 | — | | Cytology of bile juice | 1 | 5 | 1.000 | 1.0 (0.11–9.5) | | Intraductal ultrasonography | 1 | 2 | 0.421 | 2.7 (0.22–32) | | Procedure time (>45 minutes) | 2 | 8 | 0.666 | 1.3 (0.2–7.1) |
|
|
CSEMS: covered self-expandable metal stent. EST: endoscopic sphincterotomy.
|
